Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best stocks under $25 to buy now. Cantor Fitzgerald reaffirmed its Overweight rating on Summit Therapeutics Inc. (NASDAQ:SMMT) on December 19, citing a strong outlook for the company. Summit’s upcoming global phase 3 HARMONi-3 study, which will evaluate ivonescimab plus chemotherapy in first-line non-small cell lung cancer (NSCLC), was noted as a critical milestone for 2026. David Smart/Shutterstock.com Summit Therapeutics Inc. (NASDAQ:SMMT) has sta ...